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PRACTICE PERSPECTIVES
Roadmap Consensus on Carotid Artery Plaque Imaging and
Impact on Therapy Strategies and Guidelines: An International,
Multispecialty, Expert Review and Position Statement
L. Saba, W. Brinjikji, J.D. Spence, M. Wintermark, M. Castillo, G.J.D. Borst, Q. Yang, C. Yuan, A. Buckler,
M. Edjlali, T. Saam, D. Saloner, B.K. Lal, D. Capodanno, J. Sun, N. Balu, R. Naylor, A.v.d. Lugt,
B.A. Wasserman, M.E. Kooi, J. Wardlaw, J. Gillard, G. Lanzino, U. Hedin, D. Mikulis, A. Gupta, J.K. DeMarco,
C. Hess, J.V. Goethem, T. Hatsukami, P. Rothwell, M.M. Brown, and A.R. Moody
ABSTRACT
SUMMARY: Current guidelines for primary and secondary prevention of stroke in patients with carotid atherosclerosis are based
on the quantification of the degree of stenosis and symptom status. Recent publications have demonstrated that plaque morphol-
ogy and composition, independent of the degree of stenosis, are important in the risk stratification of carotid atherosclerotic dis-
ease. This finding raises the question as to whether current guidelines are adequate or if they should be updated with new
evidence, including imaging for plaque phenotyping, risk stratification, and clinical decision-making in addition to the degree of ste-
nosis. To further this discussion, this roadmap consensus article defines the limits of luminal imaging and highlights the current evi-
dence supporting the role of plaque imaging. Furthermore, we identify gaps in current knowledge and suggest steps to generate
high-quality evidence, to add relevant information to guidelines currently based on the quantification of stenosis.
ABBREVIATIONS: AHA ¼ American Heart Association; IPH ¼ intraplaque hemorrhage; LRNC ¼ lipid-rich necrotic core
Acute ischemic stroke is a major cause of morbidity and mor-tality worldwide, accounting for approximately 5% of disabil-
ity-adjusted life years and .10% of deaths. Approximately 20% of
patients with stroke/TIA have an ipsilateral carotid stenosis of
.50%,1,2 and about one-third (about 10% all patients with stroke)
had no warning symptoms such as transient ischemic attacks.3
Carotid artery stenosis is a well-established risk factor for is-
chemic stroke. Determining the best primary and secondary
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stroke prevention strategies for asymptomatic and symptomatic
patients with carotid stenosis is a priority. The current guidelines
for the management of both symptomatic and asymptomatic ath-
erosclerosis are based on randomized trials comparing medical
therapy with surgical interventions using the degree of stenosis
together with symptom status without consideration of plaque
morphology and composition. These were published before the
advent of vessel wall imaging using MR imaging and high-resolu-
tion CT angiography (Figs 1 and 2)
From the first NASCET report that demonstrated the associa-
tion between high-grade stenosis and outcome, a important evo-
lution in both the surgical approach and medical treatment has
occurred. The risk of morbidity and mortality during revasculari-
zation procedures, in particular during carotid endarterectomy,
has decreased, with a reduction of mortality and severe comp-
lications.4-6 Moreover, several trials have provided evidence
strengthening conservative medical treatment of carotid disease,
including the protective effects of high-dose statin therapy and
anti-inflammatory therapy such as the interleukin-1b innate im-
munity pathway.7-10 Recent meta-analyses provide evidence that
atherosclerosis can be reversed (“plaque regression”) with high-
dose lipid-lowering therapy,11 and high-dose statins may shift
vulnerable plaque from a high lipid content to a more stable calci-
fied plaque.11-13 Imaging of carotid plaque morphology may,
therefore, more accurately reflect the pathobiology of the plaque
itself, allowing estimation of plaque risk.14 This could lead to a
more cost-effective selection of expensive endovascular/surgical
management options.9,15
It has been.30 years since the landmark carotid surgery trials
defined the degree of carotid stenosis as an important imaging
biomarker for surgical management, leading to improved out-
comes. However, despite this advance, carotid atherosclerotic
disease still accounts for significant morbidity and mortality sug-
gesting the need for a variation in the management and risk strat-
ification of subjects with carotid artery pathology based on the
new diagnostic potentialities.
The purpose of this consensus document is to review the cur-
rent literature, identify new imaging metrics that are associated
with future cerebrovascular events and to discuss therapeutic
options for specifically targeting these features. Having done so, a
roadmap for multicenter diagnostic and therapeutic trials incor-
porating these imaging biomarkers as inclusion criteria is pro-
vided to assess patient outcome compared with management
based only on the degree of stenosis.
Summary and Analysis of Existing Guidelines
In this section, we have developed a summary and analysis of
existing guidelines. Currently, moderate (50%–69%) and severe
(70%–99%) carotid artery stenoses are considered the key param-
eters together with the symptomatic/asymptomatic status of the
patient in deciding management approaches. These are based pri-
marily on NASCET results.16,17 A report published in Stroke, in
2015,18 identified 34 guidelines from 23 different regions/coun-
tries in 6 languages, in which 4 scenarios were highlighted:
1. Asymptomatic patient at average surgical risk with stenosis
2. Asymptomatic patient at high surgical risk (because of
comorbidities, vascular anatomy, or undefined reasons) with
stenosis
3. Symptomatic patient at average surgical risk with stenosis
4. Symptomatic patient at high surgical risk (because of comorbid-
ities, vascular anatomy, or undefined reasons) with stenosis
In all 4 scenarios, the degree of stenosis ($ 50%) was the key
point considered for treatment. In 33/34 guidelines, treatment
FIG 1. Different CT features. A, Plaque ulceration (arrow) is shown with the corresponding macroscopic specimen (F). B, Multiple coarse calcifi-
cations (white arrows) within the plaque are visible with the corresponding example in the H&M histologic view (G, arrow points at a calcifica-
tion). The IPH is visible in H (white arrows) with the corresponding CTA that shows hypodense plaque in C (Hounsfield unit value = 18; white
arrow). I, A stable plaque with a prominent fibrous cap with the major part of the plaque with collagenous connective tissue (black arrow) is
shown with the corresponding CT section (D, white arrow). E, The presence of a hypodense plaque (Hounsfield unit ¼ 37) with the correspond-
ing histopathologic slide showing multiple inflammatory cells (J).
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was considered only for symptomatic subjects. For symptomatic
patients with high carotid endarterectomy risk, medical treatment
alone was not endorsed in any guidelines, though the possibility
was considered as an alternative option in 2.19-21 Only 1 guideline
advised medical treatment alone for patients with asymptomatic
carotid stenosis.
The European Society for Vascular Surgery and the European
Society of Cardiology developed consensus recommendations for
asymptomatic patients, recommending that plaque morphology
features be considered.22,23 The only variation compared with the
2011 guidelines was that carotid endarterectomy is indicated in
the presence of $1 imaging characteristic that may be associated
with high stroke risk in asymptomatic subjects. These data indi-
cate that the guidelines currently used worldwide do not consider
the imaging-based plaque morphology/composition as a parame-
ter for the therapeutic option and that the class of risk is based
on the mere degree of stenosis and symptomatic/asymptomatic
status of the patient.
However, in past years, landmark articles showing the impact
of imaging-based features of carotid artery plaque vulnerability in
symptomatic and asymptomatic patients with mild stenosis24 and
the benefit of conservative medical treatment for the plaque stabi-
lization and reversion have been published,7,9,13 highlighting the
need for changes in the forthcoming guidelines.
Evidence That Imaging of Plaque Composition Predicts
Ischemic Stroke Risk
In the past years, evidence has accumulated in pathology and
imaging fields demonstrating that plaque composition plays a
key role in the vulnerability of the carotid artery plaque.
Histopathology of Unstable Plaque. Coronary atherothrombosis
was described .150 years ago, and carotid stenosis was coupled
with the pathophysiology of ischemic stroke .70 years ago. The
associations between histopathologic features and increased risk
of stroke were described in the 1970s and 1980s, noting the asso-
ciation between fibrous cap rupture and thromboembolism (Fig
1)25-27 and identification of intraplaque hemorrhage (IPH) as a
marker of recent symptom-producing plaques.28-30
Histopathologic studies showed that vulnerable plaques were
characterized by a thin or ruptured fibrous cap, endothelial ero-
sions, enhanced inflammation, large lipid-rich necrotic cores,
immature intraplaque neovascularity, and IPH, whereas stable
and asymptomatic lesions typically contain more fibrous tissue
and more calcification.31,32
However, the authors found that ulceration, IPH, and organiz-
ing or organized thrombi were also found in both symptomatic and
asymptomatic stenotic plaques examined pathologically,29,33-40 sug-
gesting a complex pathobiologic scenario for the plaque rupture.
The authors found that biologic variability in plaque morphology
also plays a role.
Fisher and Ojemann41 noted that “the variations in the micro-
scopic appearance of the plaque contents seemed to be unend-
ing.” The authors found that the position of the lipid/necrotic
core and thinning of the cap may be the most significant features
predisposing to plaque rupture.27,40 Most interesting, decreasing
fibrous cap thickness increases the circumferential stress on a pla-
que, whereas increasing stenosis severity decreases circumferen-
tial stress.42 This finding may help to explain why stroke risk
tends to be lower in patients with critical stenosis compared with
high-grade stenosis.
The American Heart Association (AHA), in 1995, published43
a detailed classification scheme designed to be used as a histologic
template for images obtained by a variety of invasive and nonin-
vasive techniques in the clinical setting. In the AHA scheme
FIG 2. Upper row: Coregistered MPRAGE (A), T2-weighted TSE (B), pre- and postcontrast T1WI TSE MR images (C and D), and a corresponding
histologic section (E) of a cross-section of the carotid artery with plaque. A large intraplaque hemorrhage can be recognized as a hyperintense
region compared with surrounding muscle tissue in the bulk of the plaque on the MPRAGE image (arrow). Calcification can be identified as a
region with hypointense signal on all 4 MR imaging weightings. On the postcontrast T1-weighted TSE image, the region with signal enhancement
shows the fibrous cap (between the lumen and intraplaque hemorrhage). The disruption of this enhancement (white arrow) indicates that the fi-
brous cap is thin or ruptured at this location. Lower row: Coregistered TOF (F), pre- and postcontrast T1-weighted TSE MR images (G and H), and
the corresponding histologic section (I) of a cross-section of the carotid artery with a plaque. An LRNC is present in the bulk of the plaque with
no or slight contrast enhancement on the postcontrast T1WI (asterisk).
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(Table), revised in 2000,44 the lesions are designated by Roman
numerals, which indicate the usual sequence of lesion progression
from the initial lesion, type I to type VIII, in which the fibrous tis-
sue changes within the plaque predominate. This classification
was in MR imaging and CT studies (Table).45,46 Virmani et al47
built on the Stary system to more closely focus on erosion, rup-
ture, and thinning of the fibrous cap, increasingly prevalent in
the population due to widespread use of statins. The result
of these developments in plaque phenotyping have converged
into the most widely accepted system in use today,48 which also
suggests that further development will be possible once modal-
ities to recognize the lesion by noninvasive means are addressed
in this roadmap.
Plaque Vulnerability in Patients with Mild or No Stenosis.
Conventional angiography tends to underestimate the extent of
disease because the lumen can be maintained through positive
remodeling of the vessel wall, further exaggerated by the anatomy
of the carotid bulb. Patients with lesser degrees of stenosis repre-
sent a significant proportion of patients with stroke. In the
NASCET trial, .40% of those with stroke on follow-up were
from the,50% stenosis group.16 Mild stenoses, albeit associated
with reduced risk of producing ischemic events, are much more
common than severe stenoses and, thus, are associated with a
substantial number of events: The estimated prevalence of carotid
stenosis of $50% in the general population ranges from 2% to
8% and the estimated prevalence of stenosis of $80% ranges
from 1% to 2%.49 Detection of high-risk lesions in ever decreas-
ing degrees of carotid stenosis will potentially require either
higher resolution imaging or more conspicuous imaging
biomarkers.
Features of plaque vulnerability are related to the occurrence
of ischemic events independent of the degree of stenosis:
Studying plaques with lower levels of luminal stenosis separates
the effects of hemodynamic compromise caused by the luminal
narrowing and vessel wall pathology on clinical outcomes. In a
group of patients studied recently presenting with imaging-
proved acute stroke with no significant stenosis (,50%), up to
half were shown to have IPH in the carotid artery ipsilateral to
the stroke, suggesting a possible source of cerebral50,51 emboli.
Some morphologic features, such as ulceration, are also associ-
ated with the occurrence of ischemic events independent of the
degree of stenosis.52 In a meta-analysis of 8 studies including 689
patients, the presence of IPH at baseline was associated with a 6-
fold higher risk of cerebrovascular events, with an annualized
event rate of 17.7% compared with 2.43% in patients with no
IPH.53 In a separate meta-analysis of 9 studies and 779 subjects,
the hazard ratios for subsequent stroke/TIA were 4.59 for IPH,
3.00 for lipid-rich necrotic core (LRNC), and 5.93 for thin/rup-
tured fibrous cap.54 Last, another meta-analysis recently pub-
lished in 2019, including 560 patients with symptomatic and 136
patients with asymptomatic carotid stenosis, reported that the
presence of IPH at baseline increased the risk of ipsilateral stroke
both in symptomatic (hazard ratio ¼ 10.2; 95% CI, 4.6–22.5) and
asymptomatic (hazard ratio ¼ 7.9; 95% CI, 1.3–47.6) patients.
Among patients with symptomatic carotid stenosis, annualized
event rates of ipsilateral stroke in those with IPH versus those
without IPH were 9.0% versus 0.7% (,50% stenosis), 18.1% ver-
sus 2.1% (50%–69% stenosis), and 29.3% versus 1.5% (70%–99%
stenosis). Multivariate analysis identified IPH (hazard ratio ¼
11.0; 95% CI, 4.8–25.1) and a severe degree of stenosis (hazard ra-
tio¼ 3.3; 95% CI, 1.4–7.8) as independent predictors of ipsilateral
stroke.55
Plaque with Severe Stenosis and a Low Likelihood of Rupture.
Several studies have demonstrated that plaque calcification is a
stabilizing factor in carotid artery stenosis and is more common
in asymptomatic than in symptomatic plaques.56 Histopathologic
studies demonstrated that plaques with a high burden of calcifica-
tion have lower rates of inflammation, macrophage burden, neo-
vascularization, and IPH, lending further support to the use of
plaque imaging as a risk-stratification tool.14
Plaque Progression and Regression
With improvements in MR imaging, sonography, and CT, it is
now possible to directly visualize the carotid wall volume and pla-
que composition as the vessel wall disease evolves from early/
mild atherosclerosis to late-stage/severe-stage atherosclerosis.57
Progression of plaque morphology with increasing vessel wall
volume or progression of plaque components with increasing size
of vulnerable plaque features or both are associated with an
increased risk of future cerebrovascular and cardiovascular
events.58 Furthermore, direct visualization of the plaque response
to medical therapy offers the potential for individualization of
atherosclerosis treatment.59 To use imaging for assessing the
AHA classification and AHA-MR imaging–based classification
AHA Classification Carotid MR Imaging–Based AHA Classification from Cai et al45
Type I: initial lesion with foam cells Type I–II: near-normal wall thickness, no calcification
Type II: fatty streak with multiple foam cell layers
Type III: pre-atheroma with extracellular lipid pools Type III: diffuse intimal thickening or small eccentric plaque with
no calcification
Type IV: atheroma with a confluent extracellular lipid core Type IV–V: plaque with a lipid or necrotic core surrounded by
fibrous tissue with possible calcification
Type V: fibroatheroma
Type VI: complex plaque with possible surface defect, hemorrhage,
or thrombus
Type VI: complex plaque with possible surface defect, hemorrhage,
or thrombus
Type VII: calcified plaque Type VII: calcified plaque
Type VIII: fibrotic plaque without lipid core Type VIII: fibrotic plaque without lipid core and with possible small
calcifications
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response of carotid plaque to drug therapy, one needs to deter-
mine the reproducibility of the imaging.
Evidence of Plaque Progression and Regression. In a prospective,
case-controlled study of asymptomatic patients with moderate ca-
rotid stenosis, LRNC size increased in plaques with IPH compared
with plaques with no IPH.60 The role of IPH-induced plaque pro-
gression was demonstrated in a later study of mildly stenotic asymp-
tomatic patients in whom IPH was found to significantly increase
plaque size.61 This finding suggests that IPH may occur before ste-
nosis becomes severe and may drive the stenotic phenotype.59 In a
prospective study of asymptomatic patients with moderate stenosis,
the LRNC size governed the risk of future surface disruption, sug-
gesting that urgent lipid-lowering therapy to prevent the transition
from stable to unstable atherosclerotic disease may be warranted.62
Plaque progression is a major risk factor for the development of
future ischemic events. Longitudinal studies have demonstrated that
the presence of plaque hemorrhage63 (as determined by MR imag-
ing) or a hypoechoic plaque (on sonography) is a major risk factor
for plaque progression.64 Another mechanism for rapid significant
progression of plaque volume is silent plaque rupture and healing.65
With regard to evidence of plaque regression, lipid-lowering
treatment, predominately with statin therapy, has been shown to
decrease carotid plaque size and composition. Corti et al66 were
the first to show a decrease in vessel wall thickness and vessel wall
area. Observational studies have all used the 1-year timeframe to
study changes in vessel wall size.59 Because wall volume showed a
greater reduction in more diseased segments with statin ther-
apy,67 it seems that carotid MR imaging is best suited to yearly
follow-up of patients with known carotid stenosis. Studies have
shown that statin therapy is associated with a decrease in LRNC
and an increase in fibrous tissue,68 which precedes any reduction
in plaque volume.67 Information from natural history studies
suggests that IPH may override the beneficial effects of statin
therapy, but the statin type and dose were not randomized or uni-
form.61 No prospective trials exist testing the hypothesis that the
deleterious effects of IPH can be modified with very intensive
lipid-lowering therapy.
Underhill and Yuan59 summarized the use of MR imaging
monitoring of carotid plaque in clinical trials, noting the follow-
ing: 1) The rate of change is slower in plaques with ,50%
LRNC volume, though improved image quality may allow
detection of change at 6months, 2) changes in plaque composi-
tion precede changes in plaque morphology, and 3) LRNC at
baseline is needed to monitor treatment effect with MR
imaging.
Sonography provides a sensitive measure of carotid plaque
regression. Carotid plaques are focal and progress along the
artery wall 2.4 times faster than they thicken.69 Spence and
Hackam70 reported their experience in 4387 patients imaged with
serial carotid total plaque area. In this cohort, they intensified
medical therapy for patients with documented plaque progres-
sion despite guideline-based medical therapy. By “treating
arteries instead of risk factors,” they significantly decreased the
incidence of plaque progression and cardiovascular events, and
microemboli on transcranial Doppler sonography markedly
declined with intensification of medical therapy.71
Updated Drug Therapy: Evidence and Impact
It is demonstrated that a group of potentially modifiable risk fac-
tors (hypertension, regular physical activity, dyslipidemia, diet,
obesity, psychosocial factors, smoking, cardiac causes, alcohol
consumption, and diabetes mellitus) account for 90% of the pop-
ulation-attributable risks of stroke,72 and some classes of drugs
can significantly impact these factors. In this section we will
explore the latest evidence in the use of imaging and its impact
on the drug therapy in the prevention of stroke.
Lipid-Lowering Therapy. Studies have shown that treatment with
statins reduces the risk of stroke in patients at high risk for ather-
osclerosis by 21% and that this risk reduction has been associated
with each 1-mmol/L (39mg/dL) decrease in low-density lipopro-
tein.73,74 In a meta-analysis by Cannon et al,75 published in 2006,
high-intensity statin treatment reduced nonfatal cardiovascular
events and led to lower stroke incidence, even in healthy individ-
uals, with low-density lipoprotein levels of ,130mg/dL and
high-sensitivity C-reactive protein levels of .2mg/L76 Two
randomized controlled trials have shown improved cardiovas-
cular diseases outcomes with the addition of nonstatin lipid-
lowering medications: ezetimibe77 and evocolumab.78 The pro-
protein convertase subtilisin/kexin type 9 inhibitors achieve very
low nonstatin low-density lipoprotein thresholds.79 A study pub-
lished in 2016 showed that the duration of statin therapy is associ-
ated with the regression of carotid plaque neovasculature
measured with dynamic contrast-enhanced MR imaging,80 and
these results were confirmed by another group in 2019,81 again
with dynamic contrast-enhanced MR imaging, which demon-
strated that statins rapidly and significantly decreased adventitial
and plaque neovascularization at 3months.
Antiplatelet Therapy. In a study published in 1997,82 the intro-
duction of aspirin within 48 hours after ischemic stroke led to a
significant reduction in recurrence within 2weeks,83 and the
addition of dipyridamole and clopidogrel added significant bene-
fit to secondary stroke prevention.84-87 Evidence suggests that
while benefit occurs within 48 hours of starting aspirin for stroke
prevention, there is no further benefit after 2months.88 The bene-
fits of long-term treatment with dual antiplatelet therapy (aspirin
plus clopidogrel) in patients with acute coronary syndrome were
never replicated in patients with stroke and are associated with
more bleeding complications.53,62,89 The impact of antiplatelet
therapy on carotid artery plaque has been explored: in 2019, a so-
nography-based trial was published that explored the efficacy and
usefulness of an antiplatelet drug (cilostazol) on the progression
of carotid intima-media thickness, and the authors found that it
may inhibit plaque formation.90
Anticoagulation Therapy. In 2017, Eikelboom et al91 published
the results of the Cardiovascular Outcomes for People Using
Anticoagulation Strategies (COMPASS) trial. In this study,
patients with coronary, peripheral, and carotid artery disease
(symptomatic or asymptomatic) were included, and a combina-
tion of an anticoagulant (2.5mg of rivaroxaban twice a day) and
aspirin proved superior to aspirin alone and 5mg of rivaroxaban
twice a day. The outcome of ischemic and hemorrhagic events
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was significantly in favor of patients in the combined treatment
group, and efficacy outcomes were mainly driven by a 50%
relative-risk reduction in ischemic stroke risk (P, .001). The
recently published Rivaroxaban Versus Aspirin in Secondary
Prevention of Stroke and Prevention of Systemic Embolism in
Patients with Recent Embolic Stroke of Undetermined Source
(NAVIGATE ESUS) trial, performed in 4723 participants with
available intracranial CTA or MRA, showed that among partici-
pants with evidence of systemic atherosclerosis by either history
or imaging (n¼ 3820), recurrent ischemic stroke rates were simi-
lar among those assigned to rivaroxaban (5.5%/year) versus aspi-
rin (4.9%/year) (hazard ratio¼ 1.1; 95% CI, 0.84–1.5).92
Anti-Inflammatory Therapy. Atherosclerosis is considered a pre-
dominantly a lipid-driven, chronic, low-grade inflammatory dis-
ease of the arterial wall.93 Anti-inflammatory strategies are
increasingly being considered as an attractive strategy to further
reduce the residual risk of atherosclerotic cardiovascular dis-
ease.94 The administration of canakinumab (a monoclonal anti-
body against interleukin-1b ) reduces the incidence of nonfatal
myocardial infarction, nonfatal stroke, and cardiovascular death.
Colchicine is another anti-inflammatory drug that may result in
plaque stabilization,95 reducing the incidence of noncardioem-
bolic ischemic stroke in patients with stable coronary artery dis-
ease.96 Promising imaging-based studies have shown the impact
of anti-inflammatory therapy on plaque progression and compo-
sition in the coronary arteries,97 suggesting similar effects and
ability to assess them in the carotid arteries as addressed by this
roadmap.
Suggested Roadmap
There are 2 related-but-distinct clinical tasks, phenotype classifi-
cation to categorize patients to their individual disease mecha-
nism to identify the treatments to which they would most likely
respond, and risk stratification to identify how urgent interven-
tional treatments may be, to allow patients to benefit from tai-
lored therapeutics to ultimately lower or reverse disease progress
and ultimately shift the at-risk population to less acute manifesta-
tions of disease.
Sufficient data already exist to formally incorporate some pla-
que imaging in the management of atherosclerotic carotid artery
disease. It is becoming increasingly important to begin the devel-
opment of a common roadmap for changing the current standard
of practice. We propose a 4-phase roadmap (Fig 3). This section
outlines the broad overview of the roadmap, and more details are
given in the Online Supplemental Data.
Key Mover (The Phase in Which the Field Has Been).
Identification of key research questions (targets), projects (trials),
and participants (teams) necessary to change the current standard
of practice is currently confined to considering the degree of ste-
nosis and the symptom status of the patients. This change begins
by examination of existing evidence that is valuable for identify-
ing existing knowledge gaps through systematic reviews. The
results of these reviews can then be used to formulate key
research priorities for guiding the development of randomized
controlled trials. Outcomes from such randomized controlled tri-
als can then be used to initiate policy discussions, including clini-
cal implementation recommendations and the development of
new reimbursement codes as required.
Early (The Phase the Field Is Entering). In this early phase, one
introduces plaque morphology into existing medical workflows
while comparing its benefits against the established economic
and clinical values of the established standards. One must start
the development of local reimbursement codes/policies in readi-
ness for a larger body of evidence of efficacy and patient benefit.
Among the most important activities of this phase is to transition
beyond retrospective studies to prospective ones. The retrospec-
tive studies are inherently limited due to the fundamental con-
founding of the current standard of care with the incidence of
events; the ability to study positive benefits of plaque morphology
assessment as to the improvement in patient outcomes can only
be properly studied in 2-arm studies that allow study of the
hypothesized improvement without being hampered by data col-
lection that, by definition, is not allowed to use it. The data from
FIG 3. Roadmap graphic flow chart showing the 4 phases: key mover, early, mainstream, and full adoption. The lighter gray boxes represent the
components of the various stages of the roadmap. RCT indicates randomized controlled trial; SOP, standard of practice; US, ultrasound.
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these studies are expected to develop a better tool for determining
the best treatment option for atherosclerosis and inform a better
standard of care to reduce the incidence of adverse neurologic
symptomatology and poor outcome (eg, ischemic stroke) for
patients with known or suspected carotid artery disease.
Mainstream. To reach the mainstream stage, one must address
the economic impact, and indications of different organizations
should be taken into account to identify an optimal balance in
terms of diagnostic stratification of the risk and economic impact
of the process. One must establish a multicenter, multivendor
track record of techniques and patient outcomes toward perma-
nent guidelines and policy changes. A collaborative and central
data base construction for rapid, large data collection and analysis
would accelerate this process. Standardized imaging protocols
would allow accrual from both clinical (eligible retrospective and
prospective) and ongoing research imaging, with capture of
standardized patient clinical data ideally with follow-up, requir-
ing appropriate patient consent.98
Full Adoption. Results from randomized controlled trials that
examine outcome differences between the best medical treatment
compared with interventional treatment (carotid endarterec-
tomy) with treatment selection randomized to the current stand-
ards (degree of stenosis) versus plaque imaging as the new
inclusion criteria will be adopted. Change in clinical practice
would lead to an update of policies, guidelines, and billing codes.
In parallel with the stages as they effect treatment of patients with
signs and symptoms, there is an even broader application in pop-
ulation-based screening. Whereas the US Preventive Services
Task Force has presently recommended against screening,99 the
nature of these assessments is to await the development of more
powerful technologies and/or the evolution of disease prevalence
until such capability is considered to have reached a crossover
point. No doubt the stages that we have identified will provide
additional input to this process. Regardless of whether popula-
tion-based screening does or does not reach the point of being
recommended, our roadmap will meet the needs of the patients
with signs and symptoms regardless and, in so doing, increasingly
provide screening options for patient subpopulations that would
also benefit.
CONCLUSIONS
In this roadmap consensus article, we have defined the limits of
luminal imaging and highlight current evidence supporting the
role of plaque imaging in risk stratification and treatment of ca-
rotid artery atherosclerosis and stroke. These recommendations
are supported by evidence that highlights the limits of risk strati-
fication based on the degree of luminal stenosis alone and
emphasize the predictive power of other features such as the pres-
ence of IPH. Outcome trials, which confirm image-based infor-
mation and can act as a primary parameter for choosing
therapeutic interventions and predicting outcomes, are funda-
mental for the full adoption of a plaque-imaging-based approach.
This body of evidence needs to be merged with evidence from tri-
als that show the effects of pharmaceutical agents to better under-
stand the overall benefits of incorporating plaque imaging
metrics. This roadmap details the process for acquiring the neces-
sary high-quality evidence to support the incorporation of plaque
imaging in risk stratification and the management of carotid ar-
tery atherosclerotic disease.
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